Allegra-D

Quick links to important sections

Allegra-D

Method of action: Antitussive

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Allegra-D

Property Description
Active Ingredient Fexofenadine hydrochloride, Pseudoephedrine hydrochloride
Form Extended-release tablet
Pharmacological Class Upper Respiratory Combination, Second-generation Antihistamine, Sympathomimetic Decongestant
Common Purpose Management of allergy symptoms and nasal congestion
Origin Synthetic

What is Allegra-D? Understanding the Combination Product

Allegra-D is categorized as an Upper Respiratory Combination medicine, which is a fixed-dose combination product containing two synthetic active pharmaceutical ingredients in a single, oral extended-release tablet. The 'D' in the product's common name is a pharmaceutical indicator, specifically designating the inclusion of the decongestant component, which differentiates it from single-ingredient formulations. This combination formulation is noted for its ability to manage seasonal allergy symptoms when nasal or sinus congestion is present, providing a distinct advantage over single-drug treatments.


Composition and Classification of Active Ingredients

The medicine's dual action is derived from its two main components: Fexofenadine hydrochloride and Pseudoephedrine hydrochloride. Fexofenadine is classified as a selective peripheral H1-receptor antagonist (antihistamine), a type characterized by its minimal sedative effects compared to first-generation agents. Pseudoephedrine is an alpha-adrenergic agonist (sympathomimetic decongestant), whose mechanism focuses on inducing vasoconstriction. The dual presence of these components confirms the product's comprehensive utility in addressing both the core allergic reaction and the physical swelling it causes.


General Purpose: Dual-Action Symptom Management

The general purpose of this medicine is to provide dual-action symptom management, making it suitable for situations where an individual experiences both an allergic reaction and significant nasal stuffiness. Fexofenadine minimizes allergy responses by blocking histamine, while Pseudoephedrine promotes the shrinking of swollen mucous membranes. The extended-release formulation is a key feature, allowing for sustained, long-acting therapeutic effects, which is a design intended to maximize patient convenience and consistent symptom control.

Regulatory References

  1. FDA Label: Fexofenadine Hydrochloride

What side effects are possible with Allegra-D?

Possible Side Effects and Safety Information

Adverse reactions associated with the fexofenadine/pseudoephedrine combination product are formally classified based on incidence rates documented in regulatory sources, primarily affecting the Nervous System and Gastrointestinal systems. These official classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.


Documented Adverse Reactions

System-Organ Class Common Adverse Reactions (ge1%)
Nervous System Headache, Insomnia, Dizziness
Gastrointestinal Nausea, Dry Mouth
Psychiatric Nervousness, Agitation, Anxiety

Less common adverse reactions include palpitation, dyspepsia, and back pain. Post-marketing surveillance has identified rare reports such as terrifying dreams.


Safety Restrictions and Serious Events

Serious adverse reactions are rare but documented, including potentially severe Systemic Anaphylaxis (a life-threatening allergic reaction), Angioedema (swelling of the face or throat), and serious Cardiac Arrhythmias associated with the sympathomimetic component.

Regulatory documents specify Safety Restrictions (Contraindications) for use, noting that the medicine should not be taken by individuals with severe hypertension, severe coronary artery disease, narrow-angle glaucoma, or urinary retention. Use is also contraindicated in patients receiving, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI), due to the documented risk of severe blood pressure increase.

Population-Specific Safety Notes

The label includes specific considerations for certain patient groups. Individuals with renal impairment (kidney disease) may experience higher plasma levels of the components due to reduced elimination. Older adults may be more susceptible to the sympathomimetic effects. The safety and efficacy of this specific extended-release formulation have not been established for children under 12 years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for this combination medicine describes overdose manifestations stemming from both its components. The antihistamine component, fexofenadine, is documented to cause signs such as dizziness, drowsiness, dry mouth, and fatigue. Overdose involving the sympathomimetic component, pseudoephedrine, carries the potential for Central Nervous System (CNS) stimulation and severe, life-threatening outcomes.

Documented severe outcomes include convulsions, cardiac arrhythmias, circulatory collapse, coma, and respiratory failure. Due to these risks, regulatory bodies mandate that if overdose is suspected, individuals must get medical help or contact a Poison Control Center right away. Urgent medical assistance is also required if severe headache, confusion, seizures, or visual disturbances—documented manifestations of rare but serious complications—occur.

Management in an overdose scenario should follow symptomatic and supportive treatment. The official documentation notes that no specific antidote is known and that standard measures may be considered to remove unabsorbed drug. Hemodialysis is documented as not being an effective method for removing the fexofenadine component. Special considerations exist for patients with decreased renal function, who may be at a higher risk of drug accumulation and severe complications.

Therapeutic Uses of Allegra-D

The primary therapeutic role of this combination medicine is to provide comprehensive symptomatic relief for individuals aged 12 and older who experience Seasonal Allergic Rhinitis (Hay Fever) when it includes significant nasal and sinus obstruction.


This combination is applied in clinical settings that involve acute or unstable symptom patterns, particularly when symptoms related to heightened physiological activity are accompanied by those that create noticeable physiological strain due to congestion. It is commonly used to help with symptoms related to inflammatory or irritative states of seasonal allergies, including sneezing, a runny nose, itchy eyes, and nasal stuffiness.

“It is applied when symptoms cluster into patterns requiring support for both the allergic response and the accompanying swelling.”

Quick Fact: Relief for Dual Symptom Domains

This medicine is relevant for easing symptoms associated with Seasonal Allergic Rhinitis, particularly when patients experience the combination of both an allergic reaction and physical obstruction from congestion. It contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Allegra-D — official regulatory information


Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults and adolescents 12 years of age and older.

Populations for whom use is not recommended (if applicable): Children under 12 years of age; pregnant women; breastfeeding/nursing women; adults 65 years of age and older (requires consultation).

Populations for whom use is contraindicated: Patients with known hypersensitivity to ingredients; those taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of stopping; severe or uncontrolled hypertension; severe coronary artery disease; narrow-angle glaucoma; risk of urinary retention; or moderate to severe renal impairment.

Age-related eligibility rules: Use is not indicated for children under 12. Older adults must consult a doctor due to potential sensitivity.

Condition-specific eligibility rules: Consultation is required for pre-existing conditions including general kidney disease, heart disease, diabetes mellitus, or thyroid disease.

Pregnancy and lactation eligibility status (if explicitly documented): Use during pregnancy is restricted/requires consultation. Use during lactation is not recommended.

Eligibility-related restrictions: Difficulty swallowing the intact extended-release tablet is an eligibility restriction.


Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated, Restricted/Not Recommended, Caution/Consultation Required.

Regulatory basis (EMA / FDA / etc.): FDA DailyMed Prescribing Information / Health Canada.

Eligibility-context constraints (as defined in official documents): Concomitant drug use (MAOI avoidance); organ function (renal clearance limitation); cardiovascular stability.


Resulting eligibility structure

Official eligibility statements:

  • The medicine is contraindicated in patients with severe hypertension or severe coronary artery disease.
  • Use is not indicated in children under 12 years of age.
  • It is contraindicated if the patient is taking or has recently taken an MAOI.
  • Patients with moderate to severe renal impairment are contraindicated from using this medicine.
  • Use in pregnancy and lactation is not recommended without consultation.

Connection to the overall eligibility profile (2–4 sentences): The official regulatory documents define eligibility by establishing a minimum age of 12 years and enforcing several absolute contraindications that primarily relate to the safety profile of the pseudoephedrine component. Use is restricted or requires consultation based on pre-existing conditions like kidney disease, diabetes, or cardiovascular concerns, as well as status during pregnancy and lactation.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for Allegra-D, based on regulatory labeling, outlines specific combinations that are either restricted or require careful management due to potential alterations in drug levels or enhanced effects.

Contraindicated and High-Risk Combinations

The product is strictly contraindicated for use in patients taking Monoamine Oxidase (MAO) inhibitors, or within 14 days of discontinuing such treatment. This restriction is due to the potential for a dangerous increase in blood pressure or hypertensive crisis. Similarly, concurrent use with Ergot Derivatives or other sympathomimetic amines/vasoconstrictors is restricted as it may dangerously enhance blood pressure and cardiovascular effects.

Interactions Affecting Drug Levels

Several products and substances can impact the levels of the active ingredients, primarily fexofenadine. Concomitant use with Erythromycin or Ketoconazole has been shown to significantly increase the systemic exposure of fexofenadine. Conversely, Antacids containing aluminum or magnesium hydroxide can reduce fexofenadine's absorption; therefore, the product should be taken a few hours before or after antacid use. Additionally, the bioavailability of fexofenadine is significantly reduced when taken with fruit juices (including apple, orange, or grapefruit juice), and their use should be avoided while taking this medicine.

Other Noted Drug Class Interactions

The pseudoephedrine component may reduce the effectiveness of certain Antihypertensive Drugs (such as methyldopa, reserpine, and mecamylamine). Consultation with a healthcare provider is required before combining this product with antihypertensive therapies or digitalis preparations.

Mechanism of Action

Allegra-D modulates physiological function through the combined action of two distinct components: fexofenadine and pseudoephedrine.

Fexofenadine acts as a selective peripheral H1 receptor inverse agonist/antagonist. It targets peripheral histamine H1 receptors found on mast cells, smooth muscle, and endothelial cells. By binding to and stabilizing the receptor in its inactive conformation, fexofenadine prevents the activation normally induced by endogenous histamine. This blockade inhibits the Gq/11 protein-coupled pathway, thereby restricting the downstream release of intracellular calcium and the subsequent activation of Protein Kinase C (PKC). Systemically, this interaction modulates vascular permeability and smooth muscle contraction in targeted tissues.

Pseudoephedrine functions as a sympathomimetic agent, primarily acting as an agonist at alpha1-adrenergic receptors. Its mechanism also involves increasing the presynaptic release of endogenous norepinephrine, thereby promoting indirect alpha1 and beta-adrenergic receptor activation. Activation of post-junctional alpha1-adrenergic receptors on precapillary and postcapillary blood vessels in the nasal mucosa causes smooth muscle contraction. This vasoconstriction decreases blood flow to the tissue, resulting in a reduction of tissue volume.

Dosage and Administration Information

How to Use Allegra-D

The usage of Allegra-D is defined by specific administration instructions and dosage schedules. The medicine is exclusively for oral administration as a fixed-dose extended-release tablet and is typically intended for short-term relief.


Standard Dosing Regimens

Standard instructions specify two distinct formulations, each with a defined frequency:

Formulation Dosing Frequency Standard Single Dose Maximum Daily Dose
12-Hour (60 mg/120 mg) Every 12 hours (Twice daily) One tablet Two tablets
24-Hour (180 mg/240 mg) Every 24 hours (Once daily) One tablet One tablet

Administration Requirements

For proper use, the extended-release tablet must be swallowed whole and is not to be crushed, chewed, or divided. Administration must occur on an empty stomach with water, as food intake may affect the absorption of the fexofenadine component. The tablet should not be taken with fruit juices (such as grapefruit, apple, or orange) or simultaneously with aluminum or magnesium antacids, requiring a temporal separation from these substances.


Population-Specific Use

Use of Allegra-D is generally not recommended in children under 12 years of age. For the 12-hour formulation, patients with decreased renal function have a recommended starting dose of one tablet once daily (every 24 hours). The 24-hour formulation is generally advised to be avoided in patients with renal impairment. Individuals 65 years of age and older are directed to consult a health professional prior to use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Allegra-D

Evidence for Use in Seasonal Allergic Rhinitis with Nasal Congestion

Research was studied for conditions characterized by fluctuating or episodic manifestations, specifically Seasonal Allergic Rhinitis that includes nasal congestion. The primary evidence base consists of short-term controlled trials. These studies were set up to explore short-term symptom changes and examined patient-reported experiences using tools like a Total Symptom Score. This score includes outcomes related to physical discomfort such as sneezing, runny nose, and also captures outcomes related to nasal obstruction or stuffiness. Research describes patterns observed in these studies, focusing on how symptoms evolved in the observed populations during periods of increased symptom activity.

Study Design: Comparing the Combination to Placebo

Studies were primarily conducted as randomized, double-blind trials, which means that neither the participants nor the researchers knew who was receiving the combination product, an inactive treatment (placebo), or one of the product’s individual components alone. Research examined differences in measured outcomes between the combination product and those receiving the placebo. Studies monitored patient-reported outcomes describing perceived discomfort over defined time intervals. Research has also explored the difference in measured outcomes when the combination was given versus when the individual ingredients were studied alone. Objective measures, such as the use of rhinomanometry to assess nasal airflow, were also applied in studies examining the short-term physiological imbalance related to congestion.

Long-Term Research and Follow-up Durations

The evidence base relevant in trials assessing short-term or episodic symptom patterns means that follow-up durations were limited. The majority of the studies monitored effects for periods of two weeks or less. Research highlights changes measured during this acute study period. While these findings help contextualize how patients reported their experience during temporary periods of heightened symptom activity, there is limited information for long-term outcomes. Studies provide limited insight into the effects of continuous use across an entire season, and long-term effects are not fully established.

Evidence in Specific Populations

The combination product was studied for use in adults and adolescents (age 12 and older) diagnosed with Seasonal Allergic Rhinitis. Research describes patterns observed across these general age groups. Regarding older adults (age 65 and over), specific studies were conducted to examine how the body processes the ingredients. However, data for certain groups, such as those who are pregnant or individuals with specific comorbid conditions, remain insufficient. Results apply only to the populations studied, and evidence quality varies across studies when examining smaller subgroups, meaning certainty remains low in these specific populations.

What Research Still Identifies as Uncertain

Several areas where more research is needed are highlighted by the existing evidence. Since studies focused on episodes where symptoms become more noticeable, evidence is limited regarding the use of the product for chronic, year-round (perennial) allergic conditions. Follow-up durations were limited, meaning the durability of observed symptom changes is not fully established beyond the short-term trial period. Comparative evidence is also lacking when examining the combination product against every other available treatment option. Research provides context but not individual predictions, and findings highlight what is known—and what is still uncertain—about the full scope of use.

Key Studies & References Fexofenadine and Pseudoephedrine Combination: NIH National Library of Medicine Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Allegra-D (FAQ)


Q: How long does it take for Allegra-D to start working?

According to the official product information, the antihistamine component may begin its effect relatively quickly, with observation reported within 1 hour after dosing. Studies suggest the maximum antihistamine effect, which addresses allergy symptoms, is observed within 2 to 3 hours after the medicine is taken.


Q: Does Allegra-D make you drowsy or sleepy?

The fexofenadine component is officially classified as a non-sedating antihistamine, meaning it is associated with minimal sedative effects. However, due to the potential for adverse effects like dizziness or insomnia, official safety information directs that caution should be used when engaging in activities requiring mental alertness, such as driving or operating heavy machinery.


Q: Can Allegra-D cause trouble sleeping or insomnia?

Yes, regulatory documents indicate that insomnia, or trouble sleeping, is listed as a common adverse reaction associated with this combination product. This effect may be related to the pseudoephedrine component, which is classified as a sympathomimetic agent.


Q: Does Allegra-D contain stimulants that might make you feel jittery?

The pseudoephedrine component is classified as a sympathomimetic agent, which affects the nervous system. The official label lists common adverse reactions such as nervousness, agitation, and anxiety. These formally documented effects may be what some users describe colloquially as feeling 'jittery' or 'a buzz'.


Q: Are there any foods or drinks to avoid when taking Allegra-D?

Official administration guidelines advise taking the medicine on an empty stomach. Additionally, it is advised not to take the tablet with fruit juices (such as grapefruit, orange, or apple) or at the same time as aluminum or magnesium antacids.


Q: Is Allegra-D available over the counter, or do I need a prescription?

Allegra-D is generally available as an over-the-counter (OTC) medicine in the United States. However, due to the regulatory control placed on the pseudoephedrine component, it is often subject to specific governmental sales restrictions.


Q: What should I do if I accidentally take two doses close together?

The official label does not provide specific instructions for this exact scenario. In the event of accidental overdose, regulatory safety information directs that a health professional or a Poison Control Center be contacted immediately.


Q: Is Allegra-D the same as Zyrtec-D or Claritin-D?

No, they are not the same. While these products belong to the same drug class (Upper Respiratory Combination) and all contain a second-generation antihistamine plus a decongestant, they contain different active antihistamine ingredients. Allegra-D contains fexofenadine, whereas Zyrtec-D contains cetirizine, and Claritin-D contains loratadine.


Q: Can Allegra-D cause dry mouth or dry eyes?

Official regulatory documents list dry mouth (Xerostomia) as a common adverse reaction associated with the product. Although the product helps treat symptoms like itchy, watery eyes, the labels do not specifically list dry eyes as an adverse reaction.


Q: Can you drink coffee or caffeine while taking Allegra-D?

The label does not specifically mention coffee or caffeine. However, the pseudoephedrine component is a sympathomimetic agent, and its use may be associated with increased blood pressure or heart rate. Combination with other substances that may have similar effects is a factor to consider.


Q: What is the longest continuous time you can use Allegra-D?

The medicine is generally indicated by regulatory documents for short-term relief. Official labeling directs that if symptoms do not improve within 7 days or if they worsen, use should be discontinued and a health professional consulted.


Q: What organs in the body process Allegra-D?

The body primarily eliminates the fexofenadine component through the feces and, to a lesser extent, the urine. The pseudoephedrine component is also eliminated via the urine, with the rate depending on how acidic the urine is.


Q: Is it true that you shouldn't take Allegra-D with fruit juice?

Yes, official administration guidelines advise not taking the tablet with fruit juices such as grapefruit, orange, or apple. This is because these beverages can significantly decrease the absorption of the fexofenadine component.


Q: Does Allegra-D have a risk of addiction or dependency?

The official label for the combination product does not explicitly state a risk of addiction or dependency. However, the pseudoephedrine component is an adrenergic agonist, a class of drugs which, when misused, carries an inherent risk of abuse or misuse.


Q: What research is there about Allegra-D's effectiveness for seasonal allergies?

Controlled clinical trials have examined the combination product's effects in subjects with seasonal allergic rhinitis. These studies, which compared the product to placebo, observed changes in patient-reported total symptom scores, including outcomes for sneezing, runny nose, and nasal congestion.


Q: Is it safe to drive or operate machinery after taking Allegra-D?

The product label directs that caution should be used when engaging in activities requiring mental alertness, such as driving a motor vehicle or operating heavy machinery. This guidance is due to the potential for adverse effects like dizziness, nervousness, or sleeplessness.


Q: Can Allegra-D make existing anxiety worse?

Official regulatory documents list anxiety as a common adverse reaction. The sympathomimetic nature of the pseudoephedrine component may be a factor in these effects, and patients with pre-existing heart disease or thyroid disease are directed by labeling to consult a health professional prior to use.


Q: What are the signs of an allergic reaction to Allegra-D?

Official label information directs that use should be stopped and immediate medical help sought if signs of a serious allergic reaction occur. These signs may include swelling of the face, tongue, or throat, difficulty breathing, or the development of hives.


Q: Why is a limit often placed on how much Allegra-D can be purchased at once?

The product contains pseudoephedrine, an ingredient subject to government regulation due to its potential for use in the illicit manufacture of other substances. These regulations often impose daily and monthly purchase limits enforced by law.


Q: Does Allegra-D help with hives or just nasal symptoms?

The combination product is indicated for symptoms associated with seasonal allergic rhinitis, including nasal congestion. The fexofenadine component, when taken alone in certain formulations, has also been approved for the treatment of chronic idiopathic urticaria (hives).


Q: What is the usual duration of treatment with Allegra-D for a cold?

The product is indicated to temporarily relieve nasal congestion due to the common cold and is intended for short-term relief. Official labeling directs that if symptoms do not improve within 7 days, use should be discontinued and a health professional consulted.


Q: Why do some people say Allegra-D gives them a 'buzz'?

The sensation described as a 'buzz' likely relates to the sympathomimetic effects of the pseudoephedrine component. The official adverse reaction list formally documents these effects as common occurrences such as nervousness, agitation, and anxiety.


Q: Are there different strengths of Allegra-D available?

Yes, official labeling specifies two primary extended-release formulations, typically marketed as a 12-hour and a 24-hour tablet. Each formulation contains a specific amount of both the antihistamine (fexofenadine) and the decongestant component.


Q: Does Allegra-D help with sinus headache pain?

The product is indicated to temporarily relieve sinus congestion and pressure. While the label does not explicitly mention headache pain, the reduction of congestion and pressure is the mechanism intended to help alleviate associated sinus headache symptoms.


Q: Is it common to feel a change in heart rhythm with Allegra-D?

Official label information directs that if a fast or irregular heartbeat develops or if the user feels faint, use should be stopped and a health professional consulted. Less common adverse reactions include palpitation. Regulatory documents note that the drug may rarely cause serious heart rhythm disturbances.

How should Allegra-D be stored and disposed of?

Official Storage and Disposal Instructions

Official regulatory documents define strict conditions for the storage and disposal of Allegra-D extended-release tablets.

Requirement Domain Official Labeled Condition
Temperature Range Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Protection from excessive moisture and excessive heat is required.
Packaging Must be kept in the original, intact safety-sealed container.
Child Safety Keep out of the sight and reach of children.
Disposal Dispose of according to guidelines for non-flush list medicines, favoring take-back programs or secure household trash disposal as directed by the FDA.

The labeled storage temperature is essential to maintain the product's stability and the integrity of the extended-release components. Packaging must remain sealed, and if unused or expired, the medication is subject to official disposal protocols that prevent it from entering wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Allegra-D found in:

A-Z Index: